Penumbra Inc PEN
NYSE · XNYS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
6/9
Piotroski F — financial health
8.59
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $1.4B | $177.7M | $942.4M | $174.9M | $1.4B |
| 2024 | $1.2B | $14.0M | $755.0M | $147.3M | $1.2B |
| 2023 | $1.1B | $91.0M | $682.6M | $82.1M | $1.2B |
| 2022 | $847.1M | -$2.0M | $535.2M | -$75.0M | $998.9M |
| 2021 | $747.6M | $5.3M | $475.4M | -$11.7M | $953.9M |
| 2020 | $560.4M | -$15.7M | $338.2M | -$58.0M | $637.8M |
Why these scores methodology →
Piotroski F-score: 6/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 8.59 (safe)
- Working capital / assets 0.566
- Retained earnings / assets 0.13
- EBIT / assets 0.104
- Equity / liabilities 3.579
Source: SEC EDGAR filings · CIK 0001321732 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.